TrialInternational journal of cancer2025

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.

Yuan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.